Analyst firms · H.C. Wainwright · TBPH

H.C. Wainwright TBPH price target and rating history

Theravance Biopharma Inc. (TBPH) · Health Care

H.C. Wainwright rates Theravance Biopharma Inc. (TBPH) Buy with a $12 price target, as of its latest action on Feb 24, 2022. It has published 3 rating actions on TBPH since August 2021, including 0 upgrades and 0 downgrades.

Current rating
Buy
Price target
$12
Median target, all firms
Too few
Actions on TBPH
3

H.C. Wainwright price target on TBPH

$21$15$820222023202420252026
H.C. Wainwright price target on TBPH, each point a stated target, August 2021 to February 2022.

Every H.C. Wainwright rating on TBPH

How other firms rate TBPH

Each firm's latest rating and stated target in the last 12 months.

FirmRatingPrice targetDate
OppenheimerPerform$27Mar 5, 2026
B. Riley SecuritiesNeutral$14Mar 4, 2026

Questions about H.C. Wainwright and TBPH

What is H.C. Wainwright's price target for TBPH?
H.C. Wainwright's latest stated price target for Theravance Biopharma Inc. (TBPH) is $12, from its action on Feb 24, 2022.
What is H.C. Wainwright's rating on TBPH?
H.C. Wainwright rates TBPH Buy, a bullish rating, as of Feb 24, 2022.
When did H.C. Wainwright last change its view on TBPH?
On Feb 24, 2022, H.C. Wainwright raises its price target to $12 from $8, keeps Buy.

More TBPH rating histories

All H.C. Wainwright ratingsTBPH news and filingsEvery analyst firm

From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.